On April 30, 2021, Olympus announced the launch of a new product line of bronchoscopes: H-SterisSope, which was exclusively designed, developed, and produced by Huaxin Medical in China.Since then, the cooperation between the two parties has further deepened, and the level of cooperation has been further expanded.On September 19, 2023, Beijing time, Olympus, a world-renowned medical enterprise, announced the launch of its second disposable endoscope, Vathin E-SteriScope. OlympusExecutive Evaluation"We are pleased to introduce this disposable electronic rhinolaryngoscope as a complement to Olympus' otolaryngology product portfolio. We understand that many factors can affect clinical workflow, including portability, efficiency, and connectivity. The E-SteriScope disposable electronic rhinolaryngoscope provides healthcare providers with flexibility and options to balance these factors and determine the best approach for diagnosis and treatment."----Gabriel McHughSenior Vice President of Therapeutic Solutions at OlympusThe E-SteriScope disposable electronic rhinolaryngoscope is independently developed and produced by Huaxin Medical and exclusively distributed by Olympus. It is suitable for diagnosis and surgical treatment in otolaryngology. It has already been approved by the FDA and is available for sale in the United States. It will be launched in Europe, the Middle East, and Africa in the fourth quarter of this year.。E-SteriScopeHuaxindisposable electronic rhinolaryngoscopeThe outer diameter range of the diagnostic scope of the Huaxin disposable electronic rhinolaryngoscope is 3.2mm, and the outer diameter range of the therapeutic scope is 4.9mm. The insertion tube length is 300mm. As a disposable rhinolaryngoscope, it has many advantages that traditional reusable rhinolaryngoscopes do not possess.便携性：E-SteriScope允许医生在手术室或者门诊自由地为患者看病，并可以选择在更多的护理场所进行活检、注射和其它手术。Connectivity: Simplifies content management and data sharing platforms, including nCache recorder and VaultStream server, supporting collaboration between doctors and nurses, enabling them to seamlessly connect with team members and securely store and easily access patient data from one location.。Convenience: Ready to use whenever needed, the E-SteriScope offers healthcare providers a fast and effective alternative to reusable rhinolaryngoscopes. With its working channel options and workflow path solutions, the E-SteriScope enables doctors to improve surgical efficiency, reduce surgery-related costs, and enhance patient satisfaction.This year, Olympus will showcase the Huaxin disposable electronic rhinolaryngoscope and professional endoscopic minimally invasive diagnosis and treatment solutions at conferences such as the Annual Meeting of the American Rhinologic Society (ARS), the Annual Meeting of the Society of Otorhinolaryngology and Head-Neck Nurses (SOHN), and the Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO).。Founded in 1919, Olympus is a leader in the field of endoscopy. For over 100 years, it has been committed to making people's lives healthier, safer, and more fulfilling by assisting in the detection, prevention, and treatment of diseases, promoting scientific research, and ensuring public safety.。Huaxin Medical was established in 2018. With its profound technical strength, it has continuously expanded the application boundaries of disposable endoscopes and successfully developed multiple leading products in the market, establishing a leading position in the endoscope market. It is a leading enterprise in the field of disposable electronic endoscopes.。As an international giant in the field of reusable endoscopes, Olympus joined forces with Huaxin Medical in 2019 during the wave of transition from reusable endoscopes to disposable ones. Within two years, the two companies collaboratively launched two disposable endoscopes, the H-SteriScope and the E-SteriScope, successfully achieving rapid transformation.。In the future, Huaxin Medical will always regard innovation as the lasting driving force for enterprise development, continuously promote innovative technologies in domestic disposable endoscopes, maintain close cooperation with partners, explore broader markets, and win more possibilities.
Mehr
Strong allianceAugust 18th，The signing ceremony for the strategic cooperation between Hunan Huaxin Medical Instrument Co., Ltd. (hereinafter referred to as "Huaxin Medical") and Shanghai Yisi Medical Technology Co., Ltd. (hereinafter referred to as "Yisi Medical") has been successfully completed. The two parties plan to carry out long-term strategic cooperation in product research and development, commercial promotion, and marketing of disposable endoscope products worldwide.华芯医疗，liketwenty-four Huaxin Medical is an innovative leader in the field of disposable endoscopes. As one of the few companies in the world that possesses both the research and development capabilities of soft and hard endoscopes, it boasts profound technical accumulations. Huaxin Medical has applied for 434 patents both domestically and internationally, with 50 approved and valid invention patents. The company's product pipeline covers multiple departments such as respiratory, gastroenterology, urology, and otolaryngology. Its disposable bronchoscopes, ureteroscopes, cystoscopes, and other products have already obtained domestic registration certificates. Among them, the disposable bronchoscope has also obtained overseas certifications such as FDA and CE, entering developed countries like Europe, the United States, and Japan, and achieving rapid market promotion. Currently, Huaxin Medical's business has covered more than 160 countries and regions worldwide.Yisi Medical is a leading enterprise in the minimally invasive surgical instruments market, specializing in the research and development and industrialization of high-end minimally invasive surgical medical devices. It has established three major product platforms: surgical anastomosis platform, surgical energy platform, and optical imaging platform. Its product line includes laparoscopic staplers, ultrasonic scalpels, disposable endoscopes, and other innovative products, covering minimally invasive surgical procedures in the fields of the digestive system, respiratory system, and urinary system.As a national-level "specialized, sophisticated, and innovative" small giant enterprise and a brand cultivation demonstration unit, Yisi Medical has made significant achievements in technological innovation, quality casting, and brand marketing. It has made practical contributions to the localization and import substitution of high-end medical devices and the promotion and popularization of domestic minimally invasive tumor technology. It has consecutively held the leading domestic position in the field of minimally invasive tumor surgery for many years. The company's innovatively developed laparoscopic staplers, ultrasonic scalpels, and other innovative products have entered thousands of hospitals in China, with over 40% of them being tertiary hospitals. Its overseas business covers more than 70 countries and regions worldwide.The former possesses profound technological innovation and mass production capabilities in disposable endoscopes, while the latter boasts strong brand, channel resources, and platform-based commercial development capabilities. The collaboration between the two is a "powerful alliance." The two parties will jointly accelerate the clinical application, promotion, and popularization of a series of disposable endoscope products with outstanding innovative technologies in the domestic market, eliminate the risk of infection from reusable instruments, help doctors improve diagnosis and treatment efficiency, enhance patient experience, and simultaneously leverage Yisi Medical's mature global marketing network to accelerate the global market coverage of the series of disposable endoscope products.The consumables for endoscopy are the trend, Disposable endoscopes become a leading breakthrough in domestic productionDue to its advantages of minimal trauma, short surgical time, and fast recovery, minimally invasive surgery is rapidly developing in China. According to Frost Sullivan's statistics, the number of minimally invasive surgeries in China reached 15.7 million in 2021. The huge clinical demand is driving the expansion of the minimally invasive surgical instrument market, with a market size of 22.893 billion yuan (excluding endoscopes) in 2021. At present, the field of minimally invasive surgical instruments in China is still in a leading position in imports, especially in the two popular markets of endoscope and ultrasonic scalpel, which are worth billions of yuan. The localization rate needs to be improved.But at the same time, import substitution is also accelerating. The national policy vigorously promotes the localization of high-end devices, and with the support of innovative products and complete solution layout, domestic enterprises are rapidly seizing market share and achieving innovation and going global. Yisi Medical's endoscope stapler has taken the lead in increasing the bending angle of the stapler from 45 ° to 60 ° globally, surpassing similar products of international giants and achieving rapid market promotion. Huaxin Medical's disposable bronchoscope achieves smaller bending radius and larger bending angle, and has received explosive orders overseas.In the field of minimally invasive surgical instruments, which is surrounded by domestic and foreign giants, disposable endoscopes have become a breakthrough point for domestic innovative enterprises to achieve leadership. The domestic endoscope market in China started relatively late, and the degree of import monopoly in the field of reusable endoscopes is high, with high patent barriers. Domestic enterprises still have a long way to go in terms of technology accumulation and market promotion. At the same time, reusable endoscopes pose a certain risk of infection, with high unit prices and high maintenance costs for hospital disinfection, making them difficult to apply at the grassroots level. In contrast, disposable endoscopes have developed rapidly in China in recent years due to their convenient operation, no risk of infection, and low maintenance costs.The consumerism of endoscopes is a major trend, and giants such as Olympus and Boston Science are expanding into the field of disposable endoscopes. According to Boston Scientific's prediction, the global market size for disposable endoscopes will reach $2 billion by 2024. The global market for disposable endoscopes is highly concentrated, with Ambu and Boston Scientific accounting for over three-quarters of the market (based on 2020 sales revenue). However, the pattern of disposable endoscopes in China is not yet determined, leaving greater development space for domestic innovative enterprises.2022 is the "explosive period" for one-time endoscopic evidence collection in China, with over 40 domestically produced disposable endoscopes approved by the National Medical Products Administration, mainly focused on urology endoscopes. Due to differences in technical and design requirements for disposable endoscopes among different departments, domestic enterprises are gradually expanding from urology to respiratory, digestive, gynecological and other departments. Enterprises that are the first to layout multiple departments will establish a moat of time and technology.At the same time, disposable endoscopes pursue high integration and cost-effectiveness to meet the needs of graded diagnosis and treatment. Furthermore, as disposable endoscopes open up grassroots applications, the demand for mass production is higher, and market promotion also relies on the channel resources of enterprises. With the successive approval of disposable endoscope products in China, the competition in the field is becoming increasingly fierce, which increasingly tests the comprehensive strength of domestic enterprises in terms of technological innovation, mass production, and market channels.In addition, with the development of endoscopic surgery, clinical and market trends are more inclined to choose enterprises that have disposable endoscopic products and supporting surgical instruments. From a clinical perspective, using matching surgical instruments can reduce operational difficulty and risk, which is beneficial for the popularization of endoscopic surgery; From a market perspective, under centralized procurement and DRG charging, a richer product line can reduce the development risk of the enterprise, form a synergistic effect in market promotion, and expand the target market.Innovation leaders collaborate with leading enterprises, Promoting domestic innovation to achieve global developmentThis collaboration between Huaxin Medical and Yisi Medical on the research and commercialization of innovative disposable endoscopic products is promoting their global development. It is not only an innovative move in line with the trend of endoscopic consumables, but also a further improvement of both parties' product lines and integration of resources.As an innovative leader in the global disposable endoscope market, Huaxin Medical's products cover multiple departments such as respiratory, digestive, urology, and otolaryngology. The company has strong research and development capabilities, and the founding team has 16 years of experience in endoscopic technology and 10 years of experience in disposable endoscopic research and development. Its disposable endoscopic products are completely independently developed and committed to global innovation. In 2023, the number of patent applications exceeded 200. At the same time, the company acquired MGB, a century old German rigid endoscope enterprise, in 2021 to further enhance its research and development capabilities in the field of hard endoscopes.Huaxin Medical's disposable electronic bronchoscope product adopts a riveted snake bone design, which meets a bending angle of 210 degrees and a smaller bending radius. At the same time, the snake bone can be locked with any bending angle with one click after bending, ensuring precise positioning and reducing damage. This product has reached the international leading level and has obtained more than 60 certifications from China's NMPA, the US FDA, the EU CE, Japan, South Korea, and other countries. It has also partnered with the international endoscope giant Olympus as the general agent for this product line in the United States.In addition, Huaxin Medical has a production workshop and research and development building of 15600 square meters. The company independently develops production processes and equipment, such as jointly developing the world's first automated assembly equipment for endoscopes, which has high production efficiency, high quality, and controllable costs. The company can produce 1200 disposable endoscopes per day, with an annual output of 400000 units.As a leading enterprise in the field of minimally invasive surgical instruments, Yisi Medical is committed to providing complete solutions for minimally invasive surgical instruments worldwide. The company has outstanding self-developed strength, and its technological innovation strategy starts from meeting the needs of clinical and health economics. It has applied for nearly 270 domestic and foreign patents, including over 50 Chinese invention patents and over 130 international patents from countries such as Europe, America, and Japan.The core product of the endoscope stapler adopts the technology principle of robot flexible joints and double ligaments, which is the first in the world to increase the bending angle of the stapler to 60 degrees, greatly improving the convenience of doctors in narrow spaces and expanding the clinical indications for surgery. This product has applied for 7 invention patents in China and obtained nearly 20 international patents, of which two core patents have won the first prize of Shanghai Intellectual Property Innovation and the China Patent Excellence Award, and have been selected in the National Ministry of Science and Technology's Innovative Medical Device Product Catalog.At the same time, Yisi Medical's ultrasound knife products are the first domestically produced ultrasound knives approved for 5mm vascular closure through registered clinical trials in China. The waveguide rod of the ultrasound knife head adopts innovative design and has applied for an invention patent, making the vibration frequency and amplitude of the ultrasound knife head more coordinated. Yisi Medical has also taken the lead in completing the research and registration of reusable ultrasound knife heads in China, which is expected to significantly reduce surgical costs. In addition, when Yisi Medical entered the field of optical imaging, it chose to develop safer and more convenient disposable endoscopes. Its self-developed disposable electronic bladder and renal pelvis endoscope system was approved by the end of 2022.After years of development, Yisi Medical has established a relatively complete global channel network and marketing team, gained recognition from a large number of leading surgical experts KOLs worldwide, and received a large number of purchase orders from globally renowned hospitals, forming a certain brand reputation, which can quickly promote the commercialization of new products.The strong collaboration between Huaxin Medical and Yisi Medical will provide strong support for the development of the two companies, accelerating the commercialization and export of Huaxin Medical's innovative disposable endoscope products, expanding Yisi Medical's layout in the field of optical imaging, further enriching the company's minimally invasive surgical instrument solutions, fully mobilizing the resource advantages of both sides, and forming a benign development ecosystem.At the same time, in terms of clinical application, the innovative technology of domestically produced disposable endoscopes jointly promoted by the two will further improve the instrument solution for minimally invasive surgical procedures, accelerate the sinking and popularization of minimally invasive surgical procedures; At the industry level, the strategic cooperation between innovation leaders and domestic leading enterprises will strengthen their competitive advantages in the field of disposable endoscope technology, accelerate the localization process of series products, and also accelerate the reverse export of domestic innovative technologies to overseas markets, especially developed country markets.
Mehr
“Thanks to the doctor, our family can have a happy Mid-Autumn Festival together again!”Mr. Xu, a 90 year old man who was once on the brink of death, was discharged today after receiving full treatment and meticulous care from the emergency medical staff of Shibei Hospital in Jing'an District. Mr. Xu's daughter, in her 60s, tightly held the hand of the emergency department director Cao Juan and refused to let go. She gratefully said, "It's really our blessing to meet such a skilled doctor at the hospital at our doorstep!"!”Picture: Cao Juan is concentrating on performing bedside painless bronchoscopy treatment for patients. Photo by Zhu Rongbin (same below)病情反复危在旦夕The emergency department is the busiest place in hospitals, and also one of the departments with the most contact with diseases, the concentration of critically ill patients, and the heaviest rescue tasks. Most patients admitted to the emergency department have acute onset, severe condition, and rapid changes, requiring medical personnel to detect and rescue them as soon as possible, and receive precise treatment. Not long ago, 90 year old Mr. Xu, who lives on Baode Road, experienced continuous fever, coughing, phlegm, and wheezing after experiencing a "two positive" test. On the morning of September 1st, Mr. Xu's symptoms of shortness of breath suddenly worsened, accompanied by fainting. His family immediately called an ambulance to the nearest emergency room of Shibei Hospital. Dr. Xu Guangqing in the emergency department immediately performed corresponding examinations on Mr. Xu, indicating hypoxemia, inflammation of the left lower lobe of the lung, pericardium, and a small amount of pleural effusion on both sides. His condition is very serious. After preliminary examination, Mr. Xu was diagnosed as pneumonia, COVID-19 infection and hypoxemia, coronary atherosclerotic heart disease, atrial fibrillation, lacunar cerebral infarction. Further examination also revealed that the patient had multiple underlying diseases, including severe tricuspid regurgitation, moderate mitral regurgitation, pulmonary hypertension, grade 4 heart failure, and left common carotid artery stenosis with plaque formation. A significant decrease in lymphocyte count suggests extreme immune dysfunction in the elderly, suggesting infection induced bone marrow suppression. After admission to the emergency department, high flow oxygen therapy, standardized antimicrobial therapy, small molecule antiviral drugs, anticoagulation, and related symptomatic supportive treatment will be administered for about 10 days. The patient's body temperature returned to normal and heart failure was effectively controlled, but it was still found that he had hypoxemia, poor sputum production, and no significant improvement in wheezing. Re examination of chest CT shows that pneumonia has progressed compared to before, with increased pleural effusion on both sides.Dare to take responsibility for saving livesWhat should we do? Is it conservative treatment or proactive action? After Cao Juan analyzed the patient's condition, considering that Mr. Xu may be complicated by drug-resistant bacteria and fungal infection after he has COVID-19, if the infection control is not effective, it may lead to the aggravation of Mr. Xu's condition and the emergence of complications, or even death.In order to save lives and improve the quality of life of patients, Cao Juan suggests that patients undergo bedside painless bronchoscopy examination and treatment to further clarify the pathogen diagnosis, clear sputum in the airway, and guide the next step of treatment.However, the patient is not only old, but also complicated with coronary heart disease, atrial fibrillation, severe valve regurgitation, pulmonary hypertension, cardiac insufficiency, carotid stenosis, lower limb atherosclerotic plaque formation and other diseases. During bronchoscopy examination and treatment, hypoxemia and strong stimulation may further exacerbate, induce, and exacerbate the risks of heart failure, malignant arrhythmias, thrombus shedding, cerebrovascular accidents, and bleeding. If patients experience restlessness and lack of cooperation during the examination process, it may increase the risk mentioned above.Cao Juan introduced that precise diagnosis and treatment of pathogens is currently a targeted diagnosis and treatment for difficult and critically infected patients, especially those with difficult diagnosis, unclear bacterial culture, poor treatment effectiveness, and considering some special bacterial infections. It includes diagnosis and treatment measures for body fluids or tissues such as alveolar lavage fluid, blood, cerebrospinal fluid, urine, pus, feces, pleural fluid, and joint fluid, providing good guidance for improving the accuracy and cure rate of patient treatment.The reason why Cao Juan dares to take responsibility for patients and is willing to take risks is not determined by a sudden impulse or slapping her head, but by adhering to the spirit of science and relying on years of accumulated successful cases and rich experience. Cao Juan is not only proficient in carrying out new technologies such as bronchoscopic lavage, biopsy, precise pathogen diagnosis of blood and puncture fluid, monitoring of drug-resistant bacteria, development and clinical evaluation of rapid diagnosis technology for humoral pathogen infections without culture, but also proficient in interventional treatment of tumors, bronchial stenosis, foreign body removal under bronchoscopy. She is particularly skilled in the diagnosis and treatment of bronchial asthma, small airway inflammation, chronic obstructive pulmonary disease, sleep apnea syndrome, and severe infections.The patient and their family learned that Cao Juan has been practicing medicine for more than 20 years and has deep expertise in the rescue and treatment of critically ill patients, so they have great trust in Cao Juan.Accurate diagnosis and treatment to identify the "culprit"Cao Juan and her team, after careful examination, detailed analysis, and inviting anesthesia and nursing departments to jointly evaluate the relevant risks, developed personalized diagnosis and treatment plans and processes suitable for patients. After fully communicating with the patient and their family and informing them of the risks and pros and cons, Cao Juan's family expressed their agreement to undergo bronchoscopy and subsequent related examinations. When the son of the elderly man abroad learned that the doctors at Shibei Hospital were willing to take risks to examine his elderly father, he greatly admired him.Picture: Cao Juan is concentrating on performing bedside painless bronchoscopy examination and treatment for the patientWith the assistance of Deputy Director Gao Xinhai and the close cooperation of Nurse Zhang Jinmin's nursing team, Cao Juan remained calm, bold, and meticulous. With her skilled and excellent skills, she successfully performed bronchoscopy on Mr. Xu. During the surgery, it was observed that Mr. Xu's bronchial mucosa at all levels was significantly congested and edematous, with a large amount of yellow purulent phlegm and phlegm clots. He was rinsed with physiological saline and underwent alveolar lavage in both lung lobes. A small amount of alveolar lavage fluid was taken and sent to high-throughput sequencing technology (NGS) for detection. The examination process was smooth, and the patient had no severe coughing or bleeding, with stable vital signs.The next day, the NGS test results of alveolar lavage fluid returned, indicating that Streptococcus mitis, Acinetobacter baumannii and other multi drug resistant bacteria were infected, and Aspergillus fumigatus was also infected, and 2019 novel coronavirus (B.1.1.529) was detected (the previous antigen test was negative). They immediately adjusted their antimicrobial treatment plan, adding comprehensive treatments such as antifungal drugs and blocking antibodies to regulate immunity.Through a series of treatments such as high-flow oxygen therapy, immune regulation, and nutritional support, Mr. Xu's condition gradually improved and his condition stabilized, and he was finally discharged from the hospital. He was very happy and gave a thumbs up to the emergency medical staff. The patient's daughter held Cao Juan's hand and sighed, "I never expected that the hospital at our doorstep would have such a good level of medical care!"In the past month, the Emergency Department of Shibei Hospital has successfully carried out bedside painless bronchoscopy, precise pathogen diagnosis and treatment, and improved the accuracy and cure rate of treatment for 6 difficult, critical, and elderly infected patients, which has been widely recognized by patients.Illustrated: Close cooperation between medical staff, smooth operationWho is suitable for this surgeryDirector Cao Juan introduced that it is currently the high-incidence season for respiratory diseases. Bronchoscopy, as a commonly used clinical technique, has a wide range of indications and extensive diagnostic value for respiratory diseases.1、Suspected tracheal, bronchial, or lung tumors or neoplastic lesions.2、Patients with unexplained hemoptysis lasting for more than one week, especially those over 40 years old, even if no obvious abnormalities are seen on imaging.3、Patients with undiagnosed, rapidly progressing conditions, poor response to antibiotics, persistent or slowly resolving lesions, clinically diagnosed lower respiratory infections, or those with impaired immune function.4、New lung lesions after organ or bone marrow transplantation, or suspected graft-versus-host disease or immune rejection of transplanted lungs.5、Patients with unexplained, progressive, or poorly treated cough, suspected of tracheal or bronchial tumors, foreign bodies, or other lesions.6、Sudden unexplained wheezing or asthma, especially when snoring or wheezing sounds are heard in a fixed location, requiring exclusion of large airway stenosis or obstruction.7、Unexplained diffuse parenchymal lung diseases, such as interstitial pneumonia, sarcoidosis, pulmonary alveolar proteinosis, and occupational lung diseases.8、Suspected patients with airway stenosis。9、Atelectasis of a unilateral lung, lobe, or segment due to any cause。10、Suspected airway injury after trauma.11、Clinical symptoms and imaging manifestations suggesting various tracheal or bronchial fistulas, such as tracheoesophageal fistulas, bronchopleural fistulas, etc.12、Suspected airway foreign bodies.13、Unexplained mediastinal lymphadenectasis, mediastinal masses, etc。
Mehr
The mountains and rivers are adorned with splendor, while the prosperous era writes a magnificent chapter。From 1949 to 2023, after 74 years of trials and tribulations, we worked together to build our dreams and compose a magnificent chapter.Today, Huaxin people from all over the world are sending their best wishes to their motherland in different languages.I love you, China. Roots deep and leaves lush, kindness heavy and affection thick. The mountains and rivers are magnificent, and every year is full of ups and downs.Today is the 74th anniversary of the founding of our motherland. Huaxin Medical wishes our motherland eternal prosperity and peace for the people!
Mehr
Financial support from the Provincial Department of CommerceIn order to implement the spirit of the report of the "Twentieth National Congress of the Communist Party of China", actively integrate into the joint construction of the "the Belt and Road", and promote the high-quality development of foreign investment cooperation in Hunan Province, the special fund for the development of open economy and circulation industry in Hunan Province will continue to support the foreign investment cooperation business of Hunan Province in 2023。On September 18, 2023, the list of foreign investment and cooperation funding support projects for the year 2023 was determined by the Hunan Provincial Department of Commerce, and Hunan Huaxin Medical Equipment Co., Ltd. was prominently listed as a key high-tech industry to be supported. The Hunan Provincial Department of Commerce will provide preliminary cost support for Huaxin's "going global" market development and give preferential treatment to alliance projects.As a disposable electronic endoscope department enterprise, Huaxin Medical has rapidly risen since its establishment in 2018, laying the market foundation with disposable bronchi and demonstrating strong competitiveness and development potential. With profound technical strength, we continuously expand the application boundaries of disposable endoscopes, successfully develop multiple leading market products, and establish a leading position in the endoscope market. Actively expanding partners and establishing deep cooperative relationships with well-known companies such as international industry giant Olympus and leading enterprise in the minimally invasive surgical device market, Yisi Medical, to further expand market share and influence.The company has completed the construction of a 100000 level clean factory in 2019, and all important product components can be self-developed and produced. In 2021, the acquisition of MGB, a 127 year old hard mirror company in Germany, was completed, expanding into the hard mirror field. 556 patents have been applied for, including 206 invention patents. In 2023, more than 200 patents have been applied for, with invention patents accounting for 42%. Continuously approved as a national high-tech enterprise, a specialized and innovative "little giant" enterprise in Hunan Province, a new research and development institution in Hunan Province, an enterprise technology center in Hunan Province, and a benchmark enterprise in the "three products" of the consumer goods industry in Hunan Province, and included in the list of reserve resources for listing in Hunan Province (Science and Technology Innovation Board).In terms of global layout, Huaxin Medical is orderly and continues to expand its overseas market. Currently, it has established a global sales network system, selling in over 160 countries and regions, covering all mainstream regions. It is the only disposable endoscope enterprise in China that truly achieves global layout.With strong underlying research and development capabilities, excellent product performance, world leading automated production capacity for endoscopes, strong market influence, and vast development space, Huaxin Medical has become an important force that cannot be ignored in the field of endoscopes. In 2022, it established a wholly-owned subsidiary in the United States and plans to build a sales and after-sales service center and a warehousing and logistics center to further enhance its competitiveness in the global endoscopic field.In the future, Huaxin Medical will always regard innovation as the long-term driving force for enterprise development, continue to promote domestic disposable endoscope innovation technology, accelerate medical device product innovation and industrial development, and go to more countries and regions with a greater spirit of challenge, explore broader markets, and win more possibilities.
Mehr
Nachrichten sind wichtig.
Verfolge video.
Copyright © Hunan Vathin Medical Instrument Co., Ltd. Xiang ICP Record No. 19006866
